Holen Sie sich die Stockscreener-App
1.45
6.62%
0.09
Handel nachbörslich:
1.45
Erasca Inc Aktie (ERAS) Neueste Nachrichten
ERAS: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Ratio Analysis: Unpacking Northann Corp (NCL)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Erasca, Inc. (NASDAQ:ERAS) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Erasca Inc (ERAS) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Erasca, Inc. (NASDAQ:ERAS) Shares Bought by California State Teachers Retirement System - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.12 Million Stock Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Squarepoint Ops LLC Takes Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Jane Street Group LLC Cuts Stake in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Shares Purchased by Ameriprise Financial Inc. - Defense World
Nuveen Asset Management LLC Acquires 72,121 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca’s pan-KRAS inhibitor ERAS-4001 gains IND clearance - BioWorld MedTech
BNP Paribas Financial Markets Makes New Investment in Erasca, Inc. (NASDAQ:ERAS) - Defense World
FDA clears Erasca’s new cancer drug applications By Investing.com - Investing.com South Africa
Erasca Receives US FDA Approval of ERAS-4001 Investigational New Drug Application for Solid Tumors - marketscreener.com
FDA clears Erasca’s new cancer drug applications - Investing.com Australia
Erasca, Inc. Announces Ind Clearance for Potential First-In-Class and Best-In-Class Pan-Kras Inhibitor Eras-4001 - MarketScreener
Erasca (ERAS) Gains FDA Clearance for Innovative KRAS Inhibitor | ERAS Stock News - GuruFocus
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 - The Manila Times
Breakthrough: FDA Greenlights Novel Pan-KRAS Cancer Drug Targeting 2.2M Patients Worldwide - Stock Titan
ProShare Advisors LLC Raises Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Deutsche Bank AG Boosts Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Discover May 2025's Top Penny Stocks - simplywall.st
Bank of America Corp DE Has $4.88 Million Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Precision Oncology Pioneer Erasca Sets Major Investor Presentations at Jefferies and Goldman Sachs Conferences - Stock Titan
Erasca, Inc. (NASDAQ:ERAS) Shares Sold by Janus Henderson Group PLC - Defense World
D. E. Shaw & Co. Inc. Has $927,000 Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Northern Trust Corp Boosts Stock Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of “Buy” by Analysts - Defense World
Erasca Inc (NASDAQ: ERAS) Could Pass $5 In One Year Stock Forecast - Stocksregister
Price T Rowe Associates Inc. MD Buys 10,899 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
HC Wainwright Has Positive Forecast for Erasca Q2 Earnings - Defense World
Erasca (ERAS) Target Price Adjusted by Guggenheim Analyst | ERAS Stock News - GuruFocus
FDA clears Erasca’s new cancer drug ERAS-0015 By Investing.com - Investing.com India
Erasca (ERAS) Advances RAS-Targeting Therapies with New Clinical Developments | ERAS Stock News - GuruFocus
Erasca Reports First Quarter 2025 Business Updates and Financial Results - The Manila Times
Erasca, Inc. Advances RAS-Targeting Pipeline with IND Clearances and Extended Cash Runway - Nasdaq
Erasca Advances Two Novel Cancer Drugs to Clinic, Secures 3-Year Cash Runway with $411M - Stock Titan
Erasca Seeks Partner for Naporafenib to Extend Cash Runway - marketscreener.com
Erasca (ERAS) Advances RAS-Targeting Drugs with FDA Clearance | - GuruFocus
Erasca (ERAS) Advances RAS-Targeting Drugs with FDA Clearance | ERAS Stock News - GuruFocus
FDA clears Erasca’s new cancer drug ERAS-0015 - Investing.com
Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway - The Manila Times
Dimensional Fund Advisors LP Increases Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Hsbc Holdings PLC Purchases 10,458 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Shares Bought by Tower Research Capital LLC TRC - Defense World
Erasca (ERAS) Expected to Announce Quarterly Earnings on Wednesday - Defense World
MetLife Investment Management LLC Has $283,000 Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca to Present at the Bank of America Securities Health Care Conference - TradingView
Recurrent Glioblastoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Invesco Ltd. Acquires 11,290 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Barclays PLC Boosts Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Wells Fargo & Company MN Sells 73,262 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):